<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762799</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-002-1</org_study_id>
    <nct_id>NCT02762799</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®</brief_title>
  <official_title>Single-center Open Randomized Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® (JSC &quot;BIOCAD&quot;, Russia) Compared to Neupogen® (F. Hoffman-La Roche Ltd., Switzerland)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BCD-002-1 is 1 phase clinical trial to evaluate pharmacokinetics, pharmacodynamics and safety
      of single-injection of Leucostim® to healthy volunteers compared to Neupogen®
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2016</start_date>
  <completion_date type="Actual">November 11, 2016</completion_date>
  <primary_completion_date type="Actual">November 11, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (0-48 Hours)</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>Area Under Curve (AUC) &quot;concentration - time&quot; from the moment of filgrastim injection to 48 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax After Subcutaneous Injection</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>Maximal concentration of filgrastim after subcutaneous injection of filgrastim</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax After Intravenous Injection</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>Maximal concentration of filgrastim after intravenous injection of filgrastim</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax After Injection</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>Time after single injection to reach maximal concentration of filgrastim</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Т½</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>Half-life of filgrastim after single injection of filgrastim</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>The elimination rate constant after single injection of filgrastim</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>Clearance of filgrastim after single injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANC-AUEC (0-336 Hours)</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
    <description>Area Under Effect Curve (AUEC) &quot;effect - time&quot; from the moment of filgrastim injection to 336 hours based on absolute neutrophil count (ANC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANC-Emax</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
    <description>Maximal absolute neutrophil count after single filgrastim injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD34-AUEC (0-336 Hours)</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
    <description>Area Under Effect Curve (AUEC) &quot;effect - time&quot; from the moment of filgrastim injection to 336 hours based on CD-34 cells count (CD34)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD34-Emax</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
    <description>Maximal absolute count of CD34-cells after single filgrastim injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Frequency of Serious Adverse Events (SAE)</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Frequency of Adverse Events (AE)</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Local Reactions</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AE/SAE 3-4 Grade CTCAE 4.03</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
    <description>Grading scale of CTCAE 4.03
Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE:
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL (activities of daily living).
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.
Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Preliminary Withdrawal Due to AE/SAE</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Binding or Neutralizing Antibodies to Filgrastim</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
    <description>Proportion of patients who had developed binding or neutralizing antibodies to filgrastim after single injection.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Leucocytosis</condition>
  <arm_group>
    <arm_group_label>Leucostim® --&gt; Neupogen®, subcutaneous injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers in this group will receive single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neupogen® --&gt; Leucostim®, subcutaneous injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers in this group will receive single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leucostim® --&gt; Neupogen®, intravenous injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers in this group will receive single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neupogen® --&gt; Leucostim®, intravenous injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers in this group will receive single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Leucostim®</intervention_name>
    <description>Leucostim® is filgrastim biosimilar.</description>
    <arm_group_label>Leucostim® --&gt; Neupogen®, intravenous injections</arm_group_label>
    <arm_group_label>Leucostim® --&gt; Neupogen®, subcutaneous injections</arm_group_label>
    <arm_group_label>Neupogen® --&gt; Leucostim®, intravenous injections</arm_group_label>
    <arm_group_label>Neupogen® --&gt; Leucostim®, subcutaneous injections</arm_group_label>
    <other_name>filgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Neupogen®</intervention_name>
    <arm_group_label>Leucostim® --&gt; Neupogen®, intravenous injections</arm_group_label>
    <arm_group_label>Leucostim® --&gt; Neupogen®, subcutaneous injections</arm_group_label>
    <arm_group_label>Neupogen® --&gt; Leucostim®, intravenous injections</arm_group_label>
    <arm_group_label>Neupogen® --&gt; Leucostim®, subcutaneous injections</arm_group_label>
    <other_name>filgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Male gender.

          -  Age between 18 and 45 years.

          -  Normal body mass index.

          -  Verified diagnosis &quot;healthy&quot;, established according to the anamnesis, physical
             examination and laboratory findings.

          -  Absence of alcohol or drug abuse.

        Exclusion Criteria:

          -  History of use of filgrastim.

          -  Allergy to any components of study drugs.

          -  Acute hemorrhage, donation of blood / plasma or blood transfusions during last 2
             months prior to enrollment in the study, history of chronic bleeding.

          -  Surgical interventions during last 30 days prior to screening or planed surgical
             intervention during the study.

          -  Any diseases that could interfere with pharmacokinetics of filgrastim, including
             chronic liver, liver or blood diseases, diseases of cardiovascular, lung and
             neuroendocrine systems.

          -  Fever with body temperature higher than 40°С.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>JCS BIOCAD</affiliation>
  </overall_official>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>April 1, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <results_first_submitted>March 6, 2018</results_first_submitted>
  <results_first_submitted_qc>December 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2018</results_first_posted>
  <last_update_submitted>December 17, 2018</last_update_submitted>
  <last_update_submitted_qc>December 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neutrophil count</keyword>
  <keyword>filgrastim</keyword>
  <keyword>granulocyte colony-stimulating factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukocytosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Leucostim® --&gt; Neupogen®, Subcutaneous Injections</title>
          <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
        </group>
        <group group_id="P2">
          <title>Neupogen® --&gt; Leucostim®, Subcutaneous Injections</title>
          <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
        </group>
        <group group_id="P3">
          <title>Leucostim® --&gt; Neupogen®, Intravenous Injections</title>
          <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
        </group>
        <group group_id="P4">
          <title>Neupogen® --&gt; Leucostim®, Intravenous Injections</title>
          <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Leucostim® --&gt; Neupogen®, Subcutaneous Injections</title>
          <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
        </group>
        <group group_id="B2">
          <title>Neupogen® --&gt; Leucostim®, Subcutaneous Injections</title>
          <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
        </group>
        <group group_id="B3">
          <title>Leucostim® --&gt; Neupogen®, Intravenous Injections</title>
          <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
        </group>
        <group group_id="B4">
          <title>Neupogen® --&gt; Leucostim®, Intravenous Injections</title>
          <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.94" lower_limit="21.79" upper_limit="26.49"/>
                    <measurement group_id="B2" value="25.41" lower_limit="22.45" upper_limit="29.58"/>
                    <measurement group_id="B3" value="23.48" lower_limit="21.81" upper_limit="26.97"/>
                    <measurement group_id="B4" value="27.30" lower_limit="24.61" upper_limit="27.78"/>
                    <measurement group_id="B5" value="24.63" lower_limit="22.35" upper_limit="27.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-48 Hours)</title>
        <description>Area Under Curve (AUC) &quot;concentration - time&quot; from the moment of filgrastim injection to 48 hours</description>
        <time_frame>0 to 48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-48 Hours)</title>
          <description>Area Under Curve (AUC) &quot;concentration - time&quot; from the moment of filgrastim injection to 48 hours</description>
          <units>picogram per ml / hour</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168603.588" spread="47721.48"/>
                    <measurement group_id="O2" value="181152" spread="54706.439"/>
                    <measurement group_id="O3" value="411826.811" spread="204285.095"/>
                    <measurement group_id="O4" value="427355.99" spread="170878.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax After Subcutaneous Injection</title>
        <description>Maximal concentration of filgrastim after subcutaneous injection of filgrastim</description>
        <time_frame>0 to 48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax After Subcutaneous Injection</title>
          <description>Maximal concentration of filgrastim after subcutaneous injection of filgrastim</description>
          <units>picogram per ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21605.163" spread="5247.467"/>
                    <measurement group_id="O2" value="23389.559" spread="7549.536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax After Intravenous Injection</title>
        <description>Maximal concentration of filgrastim after intravenous injection of filgrastim</description>
        <time_frame>0 to 48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax After Intravenous Injection</title>
          <description>Maximal concentration of filgrastim after intravenous injection of filgrastim</description>
          <units>picogram per ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79751.577" spread="24810.907"/>
                    <measurement group_id="O2" value="90796.227" spread="25925.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax After Injection</title>
        <description>Time after single injection to reach maximal concentration of filgrastim</description>
        <time_frame>0 to 48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax After Injection</title>
          <description>Time after single injection to reach maximal concentration of filgrastim</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.5" upper_limit="2"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.5" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Т½</title>
        <description>Half-life of filgrastim after single injection of filgrastim</description>
        <time_frame>0 to 48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>Т½</title>
          <description>Half-life of filgrastim after single injection of filgrastim</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4,386" lower_limit="3,889" upper_limit="4,914"/>
                    <measurement group_id="O2" value="4,307" lower_limit="4,025" upper_limit="4,757"/>
                    <measurement group_id="O3" value="2,746" lower_limit="2,178" upper_limit="2,951"/>
                    <measurement group_id="O4" value="2,549" lower_limit="2,079" upper_limit="3,136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kel</title>
        <description>The elimination rate constant after single injection of filgrastim</description>
        <time_frame>0 to 48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>Kel</title>
          <description>The elimination rate constant after single injection of filgrastim</description>
          <units>hour-1</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.158" lower_limit="0.141" upper_limit="0.173"/>
                    <measurement group_id="O2" value="0.161" lower_limit="0.145" upper_limit="0.17"/>
                    <measurement group_id="O3" value="0.252" lower_limit="0.173" upper_limit="0.318"/>
                    <measurement group_id="O4" value="0.272" lower_limit="0.219" upper_limit="0.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance</title>
        <description>Clearance of filgrastim after single injection</description>
        <time_frame>0 to 48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance</title>
          <description>Clearance of filgrastim after single injection</description>
          <units>ml per hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2048.087" lower_limit="1893.882" upper_limit="2518.863"/>
                    <measurement group_id="O2" value="1981.707" lower_limit="1581.655" upper_limit="2439.947"/>
                    <measurement group_id="O3" value="965.938" lower_limit="595.547" upper_limit="1055.471"/>
                    <measurement group_id="O4" value="830.442" lower_limit="724.578" upper_limit="941.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ANC-AUEC (0-336 Hours)</title>
        <description>Area Under Effect Curve (AUEC) &quot;effect - time&quot; from the moment of filgrastim injection to 336 hours based on absolute neutrophil count (ANC)</description>
        <time_frame>0 to 336 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>ANC-AUEC (0-336 Hours)</title>
          <description>Area Under Effect Curve (AUEC) &quot;effect - time&quot; from the moment of filgrastim injection to 336 hours based on absolute neutrophil count (ANC)</description>
          <units>cells х10^9 per liter/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1924.284" spread="326.455"/>
                    <measurement group_id="O2" value="1933.358" spread="309.533"/>
                    <measurement group_id="O3" value="1860.922" spread="372.861"/>
                    <measurement group_id="O4" value="1895.82" spread="426.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ANC-Emax</title>
        <description>Maximal absolute neutrophil count after single filgrastim injection</description>
        <time_frame>0 to 336 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>ANC-Emax</title>
          <description>Maximal absolute neutrophil count after single filgrastim injection</description>
          <units>cells х10^9 per liter</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.285" spread="4.593"/>
                    <measurement group_id="O2" value="20.803" spread="4.097"/>
                    <measurement group_id="O3" value="20.726" spread="6.393"/>
                    <measurement group_id="O4" value="21.602" spread="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD34-AUEC (0-336 Hours)</title>
        <description>Area Under Effect Curve (AUEC) &quot;effect - time&quot; from the moment of filgrastim injection to 336 hours based on CD-34 cells count (CD34)</description>
        <time_frame>0 to 336 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>CD34-AUEC (0-336 Hours)</title>
          <description>Area Under Effect Curve (AUEC) &quot;effect - time&quot; from the moment of filgrastim injection to 336 hours based on CD-34 cells count (CD34)</description>
          <units>cell per microliter / hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1289" spread="762.292"/>
                    <measurement group_id="O2" value="1200.667" spread="761.29"/>
                    <measurement group_id="O3" value="1350.783" spread="716.645"/>
                    <measurement group_id="O4" value="1251.652" spread="562.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD34-Emax</title>
        <description>Maximal absolute count of CD34-cells after single filgrastim injection</description>
        <time_frame>0 to 336 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>CD34-Emax</title>
          <description>Maximal absolute count of CD34-cells after single filgrastim injection</description>
          <units>cell per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.694" spread="4.839"/>
                    <measurement group_id="O2" value="7.056" spread="5.248"/>
                    <measurement group_id="O3" value="9" spread="6.267"/>
                    <measurement group_id="O4" value="7.522" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Frequency of Serious Adverse Events (SAE)</title>
        <time_frame>0 to 336 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Frequency of Serious Adverse Events (SAE)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Frequency of Adverse Events (AE)</title>
        <time_frame>0 to 336 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Frequency of Adverse Events (AE)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Local Reactions</title>
        <time_frame>0 to 336 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Local Reactions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of AE/SAE 3-4 Grade CTCAE 4.03</title>
        <description>Grading scale of CTCAE 4.03
Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE:
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL (activities of daily living).
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.
Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.</description>
        <time_frame>0 to 336 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of AE/SAE 3-4 Grade CTCAE 4.03</title>
          <description>Grading scale of CTCAE 4.03
Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE:
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL (activities of daily living).
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.
Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Preliminary Withdrawal Due to AE/SAE</title>
        <time_frame>0 to 336 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Preliminary Withdrawal Due to AE/SAE</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Binding or Neutralizing Antibodies to Filgrastim</title>
        <description>Proportion of patients who had developed binding or neutralizing antibodies to filgrastim after single injection.</description>
        <time_frame>0 to 336 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucostim® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single subcutaneous injection Leucostim® on Day 29 (in Neupogen® --&gt; Leucostim® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O2">
            <title>Neupogen® Subcutaneous Injections</title>
            <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1 (in Neupogen® --&gt; Leucostim® group) or single subcutaneous injection Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group).
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O3">
            <title>Leucostim® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1 (in Leucostim® --&gt; Neupogen® group) or single intravenous injection Leucostim® on Day 29 (in Neupogen®--&gt; Leucostim® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
          <group group_id="O4">
            <title>Neupogen® Intravenous Injections</title>
            <description>Healthy volunteers in this group received single intravenous injection Neupogen® on Day 1 (in Neupogen® --&gt; Leucostim® group) or subcutaneous intravenous Leucostim® on Day 29 (in Leucostim®--&gt;Neupogen® group)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Binding or Neutralizing Antibodies to Filgrastim</title>
          <description>Proportion of patients who had developed binding or neutralizing antibodies to filgrastim after single injection.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Leucostim®, Subcutaneous Injections</title>
          <description>Healthy volunteers in this group received single subcutaneous injection Leucostim® on Day 1(in group Leucostim®--&gt;Neupogen®) or single subcutaneous injection Leucostim® on Day 29 (in group Neupogen® --&gt; Leucostim®)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
        </group>
        <group group_id="E2">
          <title>Neupogen® Subcutaneous Injections</title>
          <description>Healthy volunteers in this group received single subcutaneous injection Neupogen®, on Day 1(in group Neupogen®--&gt;Leucostim®) or single subcutaneous injection Neupogen® on Day 29 (in group Leucostim®--&gt;Neupogen®)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
        </group>
        <group group_id="E3">
          <title>Leucostim®, Intravenous Injections</title>
          <description>Healthy volunteers in this group received single intravenous injection Leucostim® on Day 1(in group Leucostim®--&gt;Neupogen®) or single subcutaneous injection Leucostim® on Day 29 (in group Neupogen® --&gt; Leucostim®)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
        </group>
        <group group_id="E4">
          <title>Neupogen®, Intravenous Injections</title>
          <description>Healthy volunteers in this group received single intravenous injection Neupogen®, on Day 1(in group Neupogen®--&gt;Leucostim®) or single subcutaneous injection Neupogen® on Day 29 (in group Leucostim®--&gt;Neupogen®)
Leucostim®: Leucostim® is filgrastim biosimilar.
Neupogen®</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphocytosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Monocytosis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>head pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yulia Linkova Medical Director</name_or_title>
      <organization>Biocad</organization>
      <phone>+7 (495) 992 66 28 ext 930</phone>
      <email>linkova@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

